Single-Center Study to Determine the Safety and Efficacy of CT-707 in Chinese Patients with Advanced Anaplastic Lymphoma Kinase-Rearranged Non-Small-Cell Lung Cancer

The study evaluated the safety and efficacy of the novel ALK inhibitor CT-707 in 13 Chinese patients with advanced ALK-rearranged non-small-cell lung cancer (NSCLC). The trial included a dose escalation phase, with doses ranging from 450 to 600 mg. The most common adverse events were diarrhea (92%), elevated liver enzymes, hair loss (38%), and vomiting. The overall response rate was 77%, with one patient achieving complete remission. The study concluded that CT-707 was clinically effective and safe for treating Chinese lung adenocarcinoma patients with ALK rearrangement, and the dose-expansion phase had begun.